Overview

SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine With ALFQ Adjuvant for Prevention of COVID-19 in Healthy Adults

Status:
Active, not recruiting

Trial end date:
2023-10-30

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety, reactogenicity, and immune response of the SpFN COVID-19 vaccine with Army Liposomal Formulation QS21 (ALFQ) adjuvant in healthy adults ages 18-55.

Phase:

Phase 1

Details

Lead Sponsor:

U.S. Army Medical Research and Development Command

Collaborators:

Henry M. Jackson Foundation for the Advancement of Military Medicine
Walter Reed Army Institute of Research (WRAIR)

Treatments:

Saponin QA-21V1